ArticleBMC cancer2020

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.

Oscar Arrieta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.